About this Research Topic
Cancer immunology and oncology have made significant strides through the integration of molecular mechanisms, immunotherapy, and drug sensitivity analysis. Understanding cancer at the molecular level has unveiled critical pathways and genetic alterations driving tumor progression and resistance to treatment. Immunotherapy has emerged as a transformative approach, harnessing the body’s immune system to target and eradicate cancer cells. Meanwhile, drug sensitivity analysis is crucial for tailoring therapies to individual patients, ensuring optimal responses and minimizing adverse effects. Despite these advances, many patients still experience limited responses or adverse effects due to varying drug sensitivities. Addressing these challenges requires a comprehensive approach that combines insights from molecular oncology with cutting-edge immunotherapeutic strategies and the systematic study of drug sensitivity.
This research topic aims to explore the intersection of these fields to uncover new therapeutic targets, optimize treatment regimens, and ultimately improve patient outcomes in oncology. Its primary goal is to address the gap between molecular insights into cancer and their practical application in improving clinical outcomes, with a particular focus on drug sensitivity. Despite significant advances in understanding cancer's molecular mechanisms, translating these discoveries into effective and personalized therapies remains a challenge. The problem lies in the complexity of cancer biology, which involves diverse genetic, epigenetic, and microenvironmental factors that contribute to tumor progression, therapy resistance, and variable drug responses. Recent advances in genomics, proteomics, and immune profiling have provided valuable insights; however, integrating these findings into actionable clinical strategies requires further exploration. To bridge this gap, this research topic will focus on several key areas: identifying and validating novel molecular targets for drug sensitivity analysis, optimizing immunotherapeutic approaches through improved patient stratification and combination therapies, and developing innovative strategies to predict and enhance drug sensitivity. By combining molecular biology with clinical research, we aim to uncover actionable strategies that enhance the efficacy of existing treatments and facilitate the development of new targeted therapies. Ultimately, the goal is to translate these advances into tangible benefits for patients, improving both survival rates and quality of life.
This research topic aims to explore the integration of molecular mechanisms, immunotherapy, and drug sensitivity in cancer immunology and oncology. Topics of this collection include but are not limited to the following:
1. Exploration of direct or indirect relationships between cancer treatments and drug sensitivity.
2. Identification and validation of novel molecular targets that influence drug sensitivity in cancer therapy.
3. Advances in immunotherapy, including checkpoint inhibitors and personalized vaccines, with a focus on their impact on drug sensitivity and patient outcomes.
4. Development of innovative strategies for predicting and enhancing drug sensitivity, including combination therapies and approaches to overcome therapeutic resistance.
5. Molecular and cellular mechanisms driving tumor progression, metastasis, and resistance to current treatments.
6. Strategies for translating molecular discoveries into effective clinical practice, including biomarker development and personalized treatment plans.
7. Optimization of patient stratification, response prediction, and individualized treatment approaches through molecular profiling and drug sensitivity testing.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
This research topic aims to explore the intersection of these fields to uncover new therapeutic targets, optimize treatment regimens, and ultimately improve patient outcomes in oncology. Its primary goal is to address the gap between molecular insights into cancer and their practical application in improving clinical outcomes, with a particular focus on drug sensitivity. Despite significant advances in understanding cancer's molecular mechanisms, translating these discoveries into effective and personalized therapies remains a challenge. The problem lies in the complexity of cancer biology, which involves diverse genetic, epigenetic, and microenvironmental factors that contribute to tumor progression, therapy resistance, and variable drug responses. Recent advances in genomics, proteomics, and immune profiling have provided valuable insights; however, integrating these findings into actionable clinical strategies requires further exploration. To bridge this gap, this research topic will focus on several key areas: identifying and validating novel molecular targets for drug sensitivity analysis, optimizing immunotherapeutic approaches through improved patient stratification and combination therapies, and developing innovative strategies to predict and enhance drug sensitivity. By combining molecular biology with clinical research, we aim to uncover actionable strategies that enhance the efficacy of existing treatments and facilitate the development of new targeted therapies. Ultimately, the goal is to translate these advances into tangible benefits for patients, improving both survival rates and quality of life.
This research topic aims to explore the integration of molecular mechanisms, immunotherapy, and drug sensitivity in cancer immunology and oncology. Topics of this collection include but are not limited to the following:
1. Exploration of direct or indirect relationships between cancer treatments and drug sensitivity.
2. Identification and validation of novel molecular targets that influence drug sensitivity in cancer therapy.
3. Advances in immunotherapy, including checkpoint inhibitors and personalized vaccines, with a focus on their impact on drug sensitivity and patient outcomes.
4. Development of innovative strategies for predicting and enhancing drug sensitivity, including combination therapies and approaches to overcome therapeutic resistance.
5. Molecular and cellular mechanisms driving tumor progression, metastasis, and resistance to current treatments.
6. Strategies for translating molecular discoveries into effective clinical practice, including biomarker development and personalized treatment plans.
7. Optimization of patient stratification, response prediction, and individualized treatment approaches through molecular profiling and drug sensitivity testing.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords: Cancer, molecular mechanisms, Immunotherapy, Oncology Drug Innovation, Tumor Microenvironment, Multi-omics, Machine Learning, Precision Oncology, Drug Sensitivity, Drug Resistance, Tumor Resistance
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
